Vanda Pharmaceuticals | VNDA - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -170.09M 28.83M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -101.31M 98.97M 2026-06
J&J USD 7.48B 860M 2026-06
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
Ligand Pharmaceuticals USD 56.62M 3.7M 2026-06
Merck USD 840M 2.72B 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Moderna USD -815M 573M 2026-06
Novartis USD 4.24B 171M 2026-03
Pfizer USD 667M 4.32B 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 2.38B 449M 2026-06
Takeda JPY 201.42B 215.04B 2026-06
Teva Pharmaceutical Industries USD 235M 523M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Veracyte USD 23.96M 4.88M 2026-06